Kenny Roman1, Christel Hall1, Anthony J Schaeffer1, Praveen Thumbikat1,2. 1. Departments of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a disorder that is characterized by persistent pelvic pain in men of any age. Although several studies suggest that the transient receptor potential vanilloid 1 (TRPV1) channel is involved in various pathways of chronic pain, the TRPV1 channel has not been implicated in chronic pelvic pain associated with CP/CPPS. METHODS: Male C57BL/6J (B6) and TRPV1 knockout (TRPV1 KO) mice (5-7 weeks old) were used to study the development of pelvic allodynia in a murine model of CP/CPPS called experimental autoimmune prostatitis (EAP). The prostate lobes, dorsal root ganglia (DRG), and spinal cord were excised at day 20. The prostate lobes were assessed for inflammation, TRPV1 expression, and mast cell activity. DRG and spinal cord, between the L6-S4 regions, were analyzed to determine the levels of phosphorylated ERK1/2 (p-ERK 1/2). To examine the therapeutic potential of TRPV1, B6 mice with EAP received intraurethral infusion of a TRPV1 antagonist at day 20 (repeated every 2 days) and pelvic pain was evaluated at days 20, 25, 30, and 35. RESULTS: Our data showed that B6 mice with EAP developed pelvic tactile allodynia at days 7, 14, and 20. In contrast, TRPV1 KO mice with EAP do not develop pelvic tactile allodynia at any time point. Although we observed no change in the levels of TRPV1 protein expression in the prostate from B6 mice with EAP, there was evidence of significant inflammation and elevated mast cell activation. Interestingly, the prostate from TRPV1 KO mice with EAP showed a lack of mast cell activation despite evidence of prostate inflammation. Next, we observed a significant increase of p-ERK1/2 in the DRG and spinal cord from B6 mice with EAP; however, p-ERK1/2 expression was unaltered in TRPV1 KO mice with EAP. Finally, we confirmed that intraurethral administration of a TRPV1 antagonist peptide reduced pelvic tactile allodynia in B6 mice with EAP after day 20. CONCLUSIONS: We demonstrated that in a murine model of CP/CPPS, the TRPV1 channel is key to persistent pelvic tactile allodynia and blocking TRPV1 in the prostate may be a promising strategy to quell chronic pelvic pain.
BACKGROUND:Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a disorder that is characterized by persistent pelvic pain in men of any age. Although several studies suggest that the transient receptor potential vanilloid 1 (TRPV1) channel is involved in various pathways of chronic pain, the TRPV1 channel has not been implicated in chronic pelvic pain associated with CP/CPPS. METHODS: Male C57BL/6J (B6) and TRPV1 knockout (TRPV1 KO) mice (5-7 weeks old) were used to study the development of pelvic allodynia in a murine model of CP/CPPS called experimental autoimmune prostatitis (EAP). The prostate lobes, dorsal root ganglia (DRG), and spinal cord were excised at day 20. The prostate lobes were assessed for inflammation, TRPV1 expression, and mast cell activity. DRG and spinal cord, between the L6-S4 regions, were analyzed to determine the levels of phosphorylated ERK1/2 (p-ERK 1/2). To examine the therapeutic potential of TRPV1, B6 mice with EAP received intraurethral infusion of a TRPV1 antagonist at day 20 (repeated every 2 days) and pelvic pain was evaluated at days 20, 25, 30, and 35. RESULTS: Our data showed that B6 mice with EAP developed pelvic tactile allodynia at days 7, 14, and 20. In contrast, TRPV1 KO mice with EAP do not develop pelvic tactile allodynia at any time point. Although we observed no change in the levels of TRPV1 protein expression in the prostate from B6 mice with EAP, there was evidence of significant inflammation and elevated mast cell activation. Interestingly, the prostate from TRPV1 KO mice with EAP showed a lack of mast cell activation despite evidence of prostate inflammation. Next, we observed a significant increase of p-ERK1/2 in the DRG and spinal cord from B6 mice with EAP; however, p-ERK1/2 expression was unaltered in TRPV1 KO mice with EAP. Finally, we confirmed that intraurethral administration of a TRPV1 antagonist peptide reduced pelvic tactile allodynia in B6 mice with EAP after day 20. CONCLUSIONS: We demonstrated that in a murine model of CP/CPPS, the TRPV1 channel is key to persistent pelvic tactile allodynia and blocking TRPV1 in the prostate may be a promising strategy to quell chronic pelvic pain.
Authors: Willem J Laursen; Eve R Schneider; Dana K Merriman; Sviatoslav N Bagriantsev; Elena O Gracheva Journal: Proc Natl Acad Sci U S A Date: 2016-09-16 Impact factor: 11.205
Authors: Christopher K Payne; Philip G Mosbaugh; John B Forrest; Robert J Evans; Kristene E Whitmore; Joseph P Antoci; Ramon Perez-Marrero; Karny Jacoby; Ananias C Diokno; Keith J O'Reilly; Tomas L Griebling; Sandip P Vasavada; Albert S Yu; Lyn R Frumkin Journal: J Urol Date: 2005-05 Impact factor: 7.450
Authors: Erik Sjögren; Lars Ståhle; Hans Quiding; Bror Jonzon; Magnus M Halldin; Anna K Sundgren Journal: Eur J Pain Date: 2019-08-14 Impact factor: 3.931
Authors: Fien C Devos; Brett Boonen; Yeranddy A Alpizar; Tania Maes; Valérie Hox; Sven Seys; Lore Pollaris; Adrian Liston; Benoit Nemery; Karel Talavera; Peter H M Hoet; Jeroen A J Vanoirbeek Journal: Eur Respir J Date: 2016-04-28 Impact factor: 16.671
Authors: László Pecze; Katalin Jósvay; Walter Blum; György Petrovics; Csaba Vizler; Zoltán Oláh; Beat Schwaller Journal: Biochim Biophys Acta Date: 2016-05-11
Authors: Elizabeth S Fernandes; Lihuan Liang; Sarah-Jane Smillie; Frank Kaiser; Robert Purcell; Damian W Rivett; Saydul Alam; Sarah Howat; Helen Collins; Stephen J Thompson; Julie E Keeble; Yanira Riffo-Vasquez; Kenneth D Bruce; Susan D Brain Journal: J Immunol Date: 2012-04-30 Impact factor: 5.422